Prescribers initiating BPC-157 in patients with Child-Pugh A or B hepatic impairment should document: (1) the clinical rationale for peptide therapy, (2) the absence of an FDA-approved alternative for the target condition, (3) baseline hepatic function with planned monitoring intervals, and (4) the patient's informed consent acknowledging the investigational nature of the therapy and the specific evidence limitations in their population
Additionally, skin irritation tests demonstrated the transdermal films were well-tolerated, showing no signs of erythema or edema even after 72 h of application
She is the Founder & Manager of MedTech Strategy Advisors, LLC and previously served as Senior Science Health Advisor at the FDAs Center for Devices and Radiological Health, where she led nationally recognized initiatives to advance womens health, health equity, and innovation in life sciences
In practice, people losing weight on GLP-1s rely on the drug to create and maintain a calorie deficit
Lord, you are the giver of all healing and the maker of every child